Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, discusses how anemia and transfusion dependence are independently prognostic of quality of life (QoL) in myelodysplastic syndromes (MDS), with reference to the EUMDS trial (NCT00600860). This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.